Share chart Neurocrine Biosciences
Main settings
Grade
Underestimation
| Title | Value | Grade |
| P/S | 6.03 | 1 |
| P/BV | 5.49 | 2 |
| P/E | 41.64 | 4 |
Efficiency
| Title | Value | Grade |
| ROA | 9.79 | 3 |
| ROE | 14.16 | 4 |
| ROIC | 5.01 | 2 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 0.7114 | 9 |
| Debt/Ratio | 0.1224 | 10 |
| Debt/Equity | 0.436 | 10 |
Growth impulse
| Title | Value | Grade |
| Revenue, % | 124.31 | 10 |
| Ebitda, % | 95.33 | 9 |
| EPS, % | -20.88 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 143.53 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 138.06 $ | 0 $ | 0 $ | +3.96 % | 0 % | 0 % |
| Month | 148.94 $ | 138.06 $ | 144.86 $ | -3.63 % | 0 % | 0 % |
| Three month | 138.94 $ | 136.63 $ | 154.8 $ | +3.3 % | 0 % | 0 % |
| Half a year | 123.02 $ | 123.98 $ | 154.8 $ | +16.67 % | 0 % | 0 % |
| Year | 123.29 $ | 87.54 $ | 154.8 $ | +16.42 % | 0 % | 0 % |
| 3 years | 93.13 $ | 87.54 $ | 154.8 $ | +54.12 % | 0 % | 0 % |
| 5 years | 103.98 $ | 73.55 $ | 154.8 $ | +38.04 % | 0 % | 0 % |
| 10 years | 6.9 $ | 32.19 $ | 154.8 $ | +1 980.14 % | 0 % | 0 % |
| Year to date | 126.7 $ | 87.54 $ | 154.8 $ | +13.28 % | 0 % | 0 % |
Insider trading
| Insider | Transaction date | Date of disclosure | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
| Gano Kyle Officer |
04.11.2025 | 05.11.2025 | Purchase | 141.97 | 4 259 | 300 | 0 | 0 | link |
| Gano Kyle Chief Executive Officer |
04.11.2025 | 04.11.2025 | Sale | 141.97 | 4 259 | 300 | 0 | 0 | link |
| Gano Kyle Chief Executive Officer |
01.11.2025 | 04.11.2025 | Purchase | 143.38 | 8 789 | 613 | 0 | 0 | link |
| BENEVICH ERIC Chief Commercial Officer |
13.02.2025 | 14.02.2025 | Sale | 116.73 | 251 436 | 2154 | 0 | 0 | link |
| BENEVICH ERIC Chief Commercial Officer |
13.02.2025 | 14.02.2025 | Purchase | 115.16 | 465 707 | 4044 | 0 | 0 | link |
| Boyer David W. Chief Corp. Affairs Officer |
13.02.2025 | 14.02.2025 | Sale | 116.74 | 208 381 | 1785 | 0 | 0 | link |
| Boyer David W. Chief Corp. Affairs Officer |
13.02.2025 | 14.02.2025 | Purchase | 115.16 | 386 016 | 3352 | 0 | 0 | link |
| Delaet Ingrid Chief Regulatory Officer |
13.02.2025 | 14.02.2025 | Sale | 116.71 | 171 680 | 1471 | 0 | 0 | link |
| Delaet Ingrid Chief Regulatory Officer |
13.02.2025 | 14.02.2025 | Purchase | 115.16 | 317 726 | 2759 | 0 | 0 | link |
| Gano Kyle Chief Executive Officer |
13.02.2025 | 14.02.2025 | Sale | 116.85 | 298 902 | 2558 | 0 | 0 | link |
| Gano Kyle Chief Executive Officer |
13.02.2025 | 14.02.2025 | Purchase | 115.16 | 553 574 | 4807 | 0 | 0.01 | link |
| ABERNETHY MATT Chief Financial Officer |
10.02.2025 | 12.02.2025 | Sale | 118.27 | 115 905 | 980 | 0 | 0 | link |
| MATTHEW C ABERNETHY Officer |
10.02.2025 | 10.02.2025 | Purchase | 122.62 | 120 168 | 980 | 0 | 0 | link |
| EIRY WYN ROBERTS Officer |
10.02.2025 | 10.02.2025 | Purchase | 122.62 | 120 168 | 980 | 0 | 0 | link |
| DARIN LIPPOLDT Officer |
10.02.2025 | 10.02.2025 | Purchase | 122.62 | 111 707 | 911 | 0 | 0 | link |
| ABERNETHY MATT Chief Financial Officer |
08.02.2025 | 12.02.2025 | Purchase | 115.16 | 214 198 | 1860 | 0 | 0 | link |
| Cooke Julie Chief Human Resources Officer |
31.01.2025 | 04.02.2025 | Sale | 152.89 | 266 029 | 1740 | 0 | 0 | link |
| Cooke Julie Chief Human Resources Officer |
31.01.2025 | 04.02.2025 | Purchase | 152.42 | 265 211 | 1740 | 0 | 0 | link |
| GORMAN KEVIN CHARLES Director |
27.01.2025 | 29.01.2025 | Sale | 149.46 | 21 836 900 | 146105 | 0 | -0.15 | link |
| GORMAN KEVIN CHARLES Director |
27.01.2025 | 29.01.2025 | Purchase | 32.99 | 4 820 000 | 146105 | 0 | 0.15 | link |
| Cooke Julie Chief Human Resources Officer |
16.07.2024 | 18.07.2024 | Sale | 150.04 | 135 036 | 900 | 0 | 0 | link |
| Cooke Julie Chief Human Resources Officer |
16.07.2024 | 18.07.2024 | Purchase | 61.82 | 55 638 | 900 | 0 | 0 | link |
| Delaet Ingrid Chief Regulatory Officer |
01.07.2024 | 02.07.2024 | Sale | 138.11 | 37 566 | 272 | 0 | 0 | link |
| Delaet Ingrid Chief Regulatory Officer |
01.07.2024 | 02.07.2024 | Purchase | 79.02 | 21 493 | 272 | 0 | 0 | link |
| Cooke Julie Chief Human Resources Officer |
01.07.2024 | 02.07.2024 | Sale | 140.19 | 1 401 900 | 10000 | 0 | -0.01 | link |
| Cooke Julie Chief Human Resources Officer |
01.07.2024 | 02.07.2024 | Purchase | 61.82 | 618 200 | 10000 | 0 | 0.01 | link |
| ABERNETHY MATT Chief Financial Officer |
08.02.2024 | 08.02.2024 | Sale | 134.21 | 131 526 | 980 | 0 | 0 | link |
| BENEVICH ERIC Chief Commercial Officer |
08.02.2024 | 08.02.2024 | Sale | 134.19 | 131 506 | 980 | 0 | 0 | link |
| Gano Kyle Chief Business Development Off |
08.02.2024 | 08.02.2024 | Sale | 134.2 | 131 516 | 980 | 0 | 0 | link |
| GORMAN KEVIN CHARLES Chief Executive Officer |
08.02.2024 | 08.02.2024 | Sale | 134.15 | 305 057 | 2274 | 0 | 0 | link |
Main owners
| Institutions | Volume | Share, % |
| Blackrock Inc. | 12 000 000 | 12.74 |
| Vanguard Group Inc | 9 000 000 | 9.74 |
| JPMorgan Chase & Co | 9 000 000 | 9.49 |
| Dodge & Cox Inc. | 5 000 000 | 5.57 |
| State Street Corporation | 4 000 000 | 4.36 |
| Price (T.Rowe) Associates Inc | 2 000 000 | 2.88 |
| AQR Capital Management, LLC | 2 000 000 | 2.78 |
| Renaissance Technologies, LLC | 2 000 000 | 2.43 |
| Geode Capital Management, LLC | 2 000 000 | 2.03 |
| Morgan Stanley | 1 000 000 | 1.83 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| PSYK ETF | 4.51 | 0 | 0.75 |
| VictoryShares Nasdaq Next 50 ETF | 1.2271 | 0.8926 | 0.18 |
| Future Tech ETF | 1.15959 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 1.15959 | -3.92 | 0.35 |
| GraniteShares XOUT U.S. Large Cap ETF | 0.80826 | -25.61 | 0.6 |
| First Trust Mid Cap US Equity Select ETF | 0.787 | -7.34 | 0.6 |
| Donoghue Forlines Innovation ETF | 0.55247 | 15.56 | 0.69 |
| Syntax Stratified MidCap ETF | 0.36602 | -0.3413 | 0.35 |
| FCF US Quality ETF | 0.29911 | 0.5065 | 0.59 |
| iShares Morningstar Mid-Cap Growth ETF | 0.22135 | 368.36 | 0.06 |
| iShares Morningstar Mid-Cap ETF | 0.1109 | 235.35 | 0.04 |
| iShares Morningstar Large-Cap Growth ETF | 0.04883 | 210.85 | 0.04 |
| iShares Factors US Growth Style ETF | 0.03532 | -6.99 | 0.25 |
| Columbia U.S. ESG Equity Income ETF | 0.02679 | -2.48 | 0.35 |
| iShares Morningstar Large-Cap ETF | 0.02418 | 182.91 | 0.03 |
Similar companies
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Matthew C. Abernethy | Chief Financial Officer | 1.04M | 1980 (45 years) |
| Mr. Eric S. Benevich | Chief Commercial Officer | 805k | 1965 (60 years) |
| Jane Sorensen | Head of Investor Relations | N/A | |
| Ms. Julie S. Cooke | Chief Human Resources Officer | N/A | 1966 (59 years) |
| Dr. Kevin C. Gorman Ph.D. | CEO & Director | 1.9M | 1958 (67 years) |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer | 621.66k | 1964 (61 year) |
| Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer | 1.04M | 1964 (61 year) |
| Mr. Darin M. Lippoldt Esq. | Chief Legal Officer & Corporate Secretary | 921.01k | 1966 (59 years) |
| Mr. Kyle W. Gano Ph.D. | Chief Business Development & Strategy Officer | 921.52k | 1973 (52 years) |
| Mr. David Warren Boyer | Chief Corporate Affairs Officer | N/A | 1980 (45 years) |
About company
Website: http://www.neurocrine.com
About Neurocrine Biosciences
Часто задаваемые вопросы по акции Neurocrine Biosciences
-
Как купить акции Neurocrine Biosciences?
Откройте брокерский счет. У крупных брокеров есть приложение или программа для торговли. Укажите название компании или тикер — NBIX. Вы можете купить минимум 1 лот, который равен 1 акции.
-
Какой налог на доходы физических лиц (НДФЛ)?
Если были начислены дивиденды или получена прибыль в результате операций купли-продажи акций NBIX. Согласно российским законам берется налог на доходы в следующем размере:
- для резидентов РФ — 13% от полученной прибыли;
- для резидентов РФ — 15%, если общий годовой доход превысил 5 млн руб. При этом повышенная ставка применяется исключительно к размеру дохода, превышающему 5 млн рублей за отчетный год;
- для нерезидентов РФ — 15% от всей суммы полученной прибыли.
Российские брокеры как налоговые агенты сами удерживают налог с граждан страны при начислении дивидендов, а также при выводе с брокерского счета денежных средств и/или в начале года, следующего за отчетным.
-
Можно ли получить налоговые льготы по акциям Neurocrine Biosciences?
В настоящее время в Российской Федерации можно получить налоговые льготы на доходы от инвестиционной деятельности, если:
- купить акции NBIX на брокерском счете и не продавать их дольше 3 лет;
- приобрести бумаги через ИИС и не выводить из него средства более 3 лет с момента открытия.
-
Какая цена акции Neurocrine Biosciences (NBIX) сегодня?
Текущая цена акции Neurocrine Biosciences на 13.12.2025 года составляет 143.53 . Котировки Neurocrine Biosciences с начала года изменилась на +13.28% - и в рублях изменение было на +16.83 .
Котировки Neurocrine Biosciences (NBIX) в этом месяце за December изменилась на -0.4405% и в рублях изменение было на -0.635 рублей.
Based on sources: porti.ru
